Palvella Therapeutics Inc (PVLA)

$100.49 +6.69 (7.13%)
Market Cap 1.19B
Revenue (ttm) 0.00
Net Income (ttm) -17.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 251,000
Avg Vol 218,334
Day's Range N/A - N/A
Shares Out 11.84M
Stochastic %K 63%
Beta -0.20
Analysts Strong Sell
Price Target $127.67

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 253 1461
Address:
125 Strafford Avenue, Suite 360, Wayne, United States
cubie
cubie Dec. 5 at 9:29 PM
$RZLT pyb $2S-$3 or 15-$20😅 $PVLA 60? Or 150?😅
0 · Reply
cubie
cubie Dec. 5 at 9:19 PM
$PVLA @judgeyoung2 oh wow data better be good , or got long way to fall
1 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 1:32 PM
Clear Street has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 12:46 PM
BTIG has updated their rating for Palvella Therapeutics ( $PVLA ) to Buy with a price target of 167.
0 · Reply
Quantumup
Quantumup Dec. 5 at 11:52 AM
BTIG🏁 $PVLA at a Buy rating and a $167 price target. Craig-Hallum y'day🏁at a Buy rating and a $175 price target. Clear Street y'day🏁at a Buy rating and a $200 PT. $SLNO $KRYS Here's what the Analysts had to say in their initiation reports:
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 5:53 PM
Craig-Hallum has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 175.
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:50 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $90.00 Put · DEC 19, 2025 Exp Entry Price: $5.00 - $7.80 Exit Price Target: $10.10 Profit Margin: +102% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
judgeyoung2
judgeyoung2 Dec. 3 at 3:33 PM
$PVLA Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:43 PM
$PTRN $PUMP $PVLA $PWB $PWR Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 1 at 10:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $90.00 Put · DEC 19, 2025 Exp Entry Price: $4.10 - $6.40 Exit Price Target: $9.84 Profit Margin: +140% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Latest News on PVLA
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 7:30 AM EST - 26 days ago

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Nov 5, 2025, 6:00 AM EST - 4 weeks ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

Nov 4, 2025, 7:30 AM EST - 4 weeks ago

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Oct 13, 2025, 7:30 AM EDT - 7 weeks ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Sep 24, 2025, 6:00 AM EDT - 2 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Sep 22, 2025, 7:30 AM EDT - 2 months ago

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Sep 17, 2025, 7:30 AM EDT - 2 months ago

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Sep 15, 2025, 7:30 AM EDT - 2 months ago

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Sep 3, 2025, 7:30 AM EDT - 3 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 3 months ago

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Jun 23, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Jun 18, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Jun 9, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025, 8:00 AM EDT - 6 months ago

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

May 5, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Apr 23, 2025, 4:15 PM EDT - 8 months ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 22, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Apr 11, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Mar 18, 2025, 8:30 AM EDT - 9 months ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 10 months ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Feb 10, 2025, 8:00 AM EST - 10 months ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Dec 13, 2024, 2:55 PM EST - 1 year ago

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

cubie
cubie Dec. 5 at 9:29 PM
$RZLT pyb $2S-$3 or 15-$20😅 $PVLA 60? Or 150?😅
0 · Reply
cubie
cubie Dec. 5 at 9:19 PM
$PVLA @judgeyoung2 oh wow data better be good , or got long way to fall
1 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 1:32 PM
Clear Street has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 12:46 PM
BTIG has updated their rating for Palvella Therapeutics ( $PVLA ) to Buy with a price target of 167.
0 · Reply
Quantumup
Quantumup Dec. 5 at 11:52 AM
BTIG🏁 $PVLA at a Buy rating and a $167 price target. Craig-Hallum y'day🏁at a Buy rating and a $175 price target. Clear Street y'day🏁at a Buy rating and a $200 PT. $SLNO $KRYS Here's what the Analysts had to say in their initiation reports:
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 5:53 PM
Craig-Hallum has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 175.
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:50 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $90.00 Put · DEC 19, 2025 Exp Entry Price: $5.00 - $7.80 Exit Price Target: $10.10 Profit Margin: +102% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
judgeyoung2
judgeyoung2 Dec. 3 at 3:33 PM
$PVLA Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:43 PM
$PTRN $PUMP $PVLA $PWB $PWR Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 1 at 10:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $90.00 Put · DEC 19, 2025 Exp Entry Price: $4.10 - $6.40 Exit Price Target: $9.84 Profit Margin: +140% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
stockmoe12
stockmoe12 Nov. 26 at 6:50 PM
$QNRX $PVLA 100+ … next qnrx
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 2:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $90.00 Put · DEC 19, 2025 Exp Entry Price: $4.10 - $8.50 Exit Price Target: $9.39 Profit Margin: +129% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 25 at 2:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $70.00 Put · NOV 21, 2025 Exp Entry Price: $2.32 - $5.00 Exit Price Target: $5.38 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
aletz
aletz Nov. 24 at 10:04 PM
$PVLA https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ PVLA demonstrated resilience amidst market volatility, securing a position in the top 10 of my weekly AI scanner.
0 · Reply
ap20
ap20 Nov. 24 at 7:58 PM
$PVLA Love the small float, small watchers, and the large way it goes up. ‘Will add some more if it gets back in double figures.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 24 at 5:37 PM
$PVLA Stifel Maintains Buy on Palvella Therapeutics, Raises Price Target to $145
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 5:35 PM
Stifel has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 87 → 145.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:57 PM
$PTRN $PUMP 🔥 $PVLA $PWB $PWR
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 23 at 4:22 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $70.00 Put · NOV 21, 2025 Exp Entry Price: $2.32 - $5.00 Exit Price Target: $5.38 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
stockmoe12
stockmoe12 Nov. 22 at 12:42 AM
$QNRX slow and steady .. like $PVLA
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 11:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PVLA $70.00 Put · NOV 21, 2025 Exp Entry Price: $2.32 - $5.00 Exit Price Target: $5.38 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
CH_Expat
CH_Expat Nov. 21 at 8:03 PM
$PVLA Congrats man. Too late for now for me,but watching carefully.
0 · Reply